• Company Information
  • Business Outline
  • Pipeline
  • IR Information
  • Contact
Breakthrough virotherapy for cancer

Oncolys BioPharma continuously evolve its business to develop breakthrough therapy and diagnostics in cancer treatment from early to late stage, including early detection, loco-regional therapy, prognostic test, and systemic treatments.
Our mission is to help both patients and physicians through developing effective and innovating drugs.

Information Past News
May. 6, 2016
News Release
Oncolys BioPharma proudly participates in BIOtech Japan 2016 from 11th to 13th May at Tokyo Big Sight
Apr. 6, 2016
Others
Our business partner,LIQUID BIOTECH USA, INC. announcing a completion of Proof-Of-Concept (POC) clinical study that triggers a $1M milestone payment from Oncolys BioPharma, Inc.
Mar. 19, 2016
News Release
The 88th Annual Meeting of Japanese Gastric Cancer Association - OBP-301 (Telomelysin®) introduced in a luncheon seminar "The trends of new drug development for the treatment of advanced gastric cancer"
Mar. 3, 2016
Publications
The paper relating to TelomeScan® was published on"Molecular Therapy — Methods & Clinical Development"
Feb. 23, 2016
News Release
The 23rd International Annual Molecular Med TRI-CON 2016, San Francisco, CA. - our TelomeScan® research collaborator Dr. Dorsey (Department of Radiation Oncology, University of Pennsylvania) to hold a luncheon seminar on Wed 9 March, to discuss the association of "telomerase-dependent CTC findings" with treatment response in a variety of cancer patient populations.
Feb. 22, 2016
Others
Our business partner,LIQUID BIOTECH USA, INC. was selected as a finalist in the 2016 Enterprise Awards Life Sciences Startup Category by PACT.
Jan. 19, 2016
News Release
Our diagnostic business was featured in TV TOKYO's program "Medical office where the chief physician is found in", broadcasted on 18 Jan 2016.
Dec. 14, 2015
News Release
License agreement and business alliance with Liquid Biotech USA, Inc. for cancer detection modality OBP-401 (TelomeScan®)
Dec. 1, 2015
News Release
OBP-401 (TELOMESCAN™) ADOPTED IN CLINICAL TRIALS FOR THE DEVELOPMENT OF NOVEL MOLECULAR TARGETED ANTI-CANCER AGENTS
Nov. 24, 2015
News Release
Announcement of TelomeScan® License Agreement and Business Alliance in North America
pagetop